Drug Trial Radar · NCT05862285
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
Mar 1, 2033
Study completion Mar 1, 2033
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Conditions
- Cancer
Interventions
IpatasertibDrug
Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
TiragolumabDrug
Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
AtezolizumabDrug
Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
Tiragolumab and AtezolizumabDrug
Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
BevacizumabDrug
Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
EntrectinibDrug
Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
InavolisibDrug
Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
DivarasibDrug
Divarasib will be administered as a monotherapy or in combination with atezolizumab or bevacizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
GiredestrantDrug
Giredestrant will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)Time frame: Up to approximately 10 years
- Number and Severity of Participants With Selected Adverse Events Assessed as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0Time frame: Up to approximately 10 years
Locations
85 sites in 15 countries. Site status is shown where the registry gives one.
GHdC Site Les Viviers
Charleroi, Belgium · Completed
AZ Groeninge
Kortrijk, Belgium · Active not recruiting
UZ Leuven Gasthuisberg
Leuven, Belgium · Completed
UZ Leuven Gasthuisberg
Leuven, Belgium · Active not recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
the First Hospital of Jilin University
Changchun, China · Recruiting
West China Hospital of Sichuan University
Chengdu, China · Recruiting
Cancer Center of Guangzhou Medical University
Guangzhou, China · Recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, China · Recruiting
Zhejiang People's Hospital
Hangzhou, China · Recruiting
Sir Run Run Shaw Hospital Zhejiang University
Hangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei, China · Recruiting
Meizhou People's Hospital
Meizhou, China · Recruiting
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, China · Recruiting
Jiangsu Province Hospital of Chinese Medicine
Nanjing, China · Recruiting
Shanghai Chest Hospital
Shanghai, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Shanghai Geriatric Medical Center
Shanghai, China · Recruiting
Tianjin Cancer Hospital
Tianjin, China · Recruiting
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, China · Recruiting
Xi'an International Medical Center Hospital
Xi'an, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China · Recruiting
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
XI 'an City, Shaanxi Province, Shaanxi, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Clinica CIMCA
San José, Costa Rica · Active not recruiting
ICIMED Instituto de Investigación en Ciencias Médicas
San José, Costa Rica · Active not recruiting
Institut Bergonie
Bordeaux, France · Recruiting
Centre Francois Baclesse
Caen, France · Recruiting
Institut de Cancérologie de Bourgogne
Dijon, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Hopital de la Timone
Marseille, France · Recruiting
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
Montpellier, France · Recruiting
CHU de Nantes - Hotel Dieu
Nantes, France · Recruiting
Institut de cancerologie du Gard
Nîmes, France · Completed
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.